Benzinga

Benzinga

Benzinga

vendredi, septembre 04

BridgeBio Pharma Inc

BBIONASDAQ
Trade with Public
Trade with Public
$75.41
-1.09-1.42%
À la clôture: Sep 2, 5:00 PM EST
$75.45
-1.05-1.37%
Pré-ouverture: 3:00 AM EST
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatComparerOptionsRapport sur les stocks

BridgeBio Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for BridgeBio Pharma (BBIO).

Price Target Range — 9 Quarters

Analyst Consensus — 25 Analysts

23Buy
2Hold
Consensus RatingBuy# Analysts25Avg. Consensus PT$91Upside to Avg. PT+21.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Sep 2, 2026HC Wainwright & Co.Raghuram SelvarajuMaintainedBuy$120
Sep 1, 2026MizuhoSalim SyedPT RaiseOutperform$96→$110
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $120 price target.
Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on BridgeBio Pharma, Raises Price Target to $110

Mizuho analyst Salim Syed maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and raises the price target from $96 to $110.
Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $107

Truist Securities analyst Danielle Brill maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $102 to $107.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on BridgeBio Pharma, Raises Price Target to $106

Canaccord Genuity analyst Whitney Ijem maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $104 to $106.
Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on BridgeBio Pharma, Raises Price Target to $111

JP Morgan analyst Anupam Rama maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $100 to $111.
Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $104

B of A Securities analyst Geoff Meacham maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $101 to $104.
Benzinga Newsdesk

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Données de marché fournies par API Benzinga

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved